{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:39:39Z","timestamp":1783741179019,"version":"3.55.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ejpb.2022.10.002","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T23:10:59Z","timestamp":1665097859000},"page":"201-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Existing and emerging mitigation strategies for the prevention of accidental overdose from oral pharmaceutical products"],"prefix":"10.1016","volume":"180","author":[{"given":"Mubtasim","family":"Murshed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malinda","family":"Salim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben J.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2022.10.002_b0005","unstructured":"J.J. Li. Top drugs : Their History, Pharmacology, and Syntheses. New York: Oxford University Press; 2015."},{"issue":"12","key":"10.1016\/j.ejpb.2022.10.002_b0010","doi-asserted-by":"crossref","first-page":"e81355","DOI":"10.1371\/journal.pone.0081355","article-title":"Closing the Gap: Increases in Life Expectancy among Treated HIV-positive Individuals in the United States and Canada","volume":"8","author":"Samji","year":"2013","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.ejpb.2022.10.002_b0015","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1113\/EP086205","article-title":"Why and how are we living longer?","volume":"102","author":"Kirkwood","year":"2017","journal-title":"Exp. Physiol."},{"issue":"50\u201351","key":"10.1016\/j.ejpb.2022.10.002_b0020","first-page":"1378","article-title":"Increases in Drug and Opioid Overdose Deaths - United States, 2000\u20132014","volume":"64","author":"Rudd","year":"2016","journal-title":"MMWR."},{"issue":"11","key":"10.1016\/j.ejpb.2022.10.002_b0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2105\/AJPH.2015.302843","article-title":"Worldwide Prevalence and Trends in Unintentional Drug Overdose: A Systematic Review of the Literature","volume":"105","author":"Martins","year":"2015","journal-title":"Am. J. Public Health"},{"issue":"1","key":"10.1016\/j.ejpb.2022.10.002_b0030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40122-018-0096-7","article-title":"A Review of the Opioid Epidemic: What Do We Do About It?","volume":"7","author":"Shipton","year":"2018","journal-title":"Pain Ther."},{"issue":"1","key":"10.1016\/j.ejpb.2022.10.002_b0035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/089719000001300106","article-title":"Drug Poisoning and Overdose for the Health Professional: Review of Select Over-the-Counter (OTC) and Prescription Medications","volume":"13","author":"Laven","year":"2000","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.ejpb.2022.10.002_b0040","unstructured":"H. Hedegaard, M. Warner, A. Mini\u00f1o. Drug Overdose Deaths in the United States, 1999\u20132016. Hyattsville, MD: National Centre for Health Statistics; 2017."},{"issue":"10","key":"10.1016\/j.ejpb.2022.10.002_b0045","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s11606-013-2390-8","article-title":"Preventing Prescription Opioid Overdose Deaths","volume":"28","author":"Rastegar","year":"2013","journal-title":"J. Gen. Intern. Med."},{"issue":"2","key":"10.1016\/j.ejpb.2022.10.002_b0050","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/204946371000400203","article-title":"Transdermal Opioids for Cancer Pain Management","volume":"4","author":"Vithlani","year":"2010","journal-title":"Rev Pain."},{"issue":"2","key":"10.1016\/j.ejpb.2022.10.002_b0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/add.12224","article-title":"Non-medical use of prescription opioids and prescription opioid-related harms: why so markedly higher in North America compared to the rest of the world?","volume":"109","author":"Fischer","year":"2014","journal-title":"Addiction."},{"issue":"4","key":"10.1016\/j.ejpb.2022.10.002_b0060","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jsat.2012.08.010","article-title":"Prescription opioid abuse, chronic pain, and primary care: A Co-Occurring Disorders Clinic in the chronic disease model","volume":"43","author":"Pade","year":"2012","journal-title":"J. Subst. Abuse Treat."},{"issue":"10","key":"10.1016\/j.ejpb.2022.10.002_b0065","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/add.13741","article-title":"Do more robust prescription drug monitoring programs reduce prescription opioid overdose?","volume":"112","author":"Pardo","year":"2017","journal-title":"Addiction."},{"issue":"2","key":"10.1016\/j.ejpb.2022.10.002_b0070","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0304-3959(86)90091-6","article-title":"Chronic use of opioid analgesics in non-malignant pain: Report of 38 cases","volume":"25","author":"Portenoy","year":"1986","journal-title":"Pain"},{"key":"10.1016\/j.ejpb.2022.10.002_b0075","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4088\/JCP.10com06560","article-title":"A National Epidemic of Unintentional Prescription Opioid Overdose Deaths: How Physicians Can Help Control It","volume":"72","author":"Paulozzi","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.ejpb.2022.10.002_b0080","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1097\/PR9.0000000000000599","article-title":"The opioid epidemic and national guidelines for opioid therapy for chronic noncancer pain: a perspective from different continents","volume":"2","author":"H\u00e4user","year":"2017","journal-title":"Pain Rep."},{"issue":"2","key":"10.1016\/j.ejpb.2022.10.002_b0085","doi-asserted-by":"crossref","first-page":"e180216","DOI":"10.1001\/jamanetworkopen.2018.0216","article-title":"Patterns of Immediate-Release and Extended-Release Opioid Analgesic Use in the Management of Chronic Pain, 2003\u20132014","volume":"1","author":"Hwang","year":"2018","journal-title":"JAMA Netw Open."},{"key":"10.1016\/j.ejpb.2022.10.002_b0090","unstructured":"Prescribing drugs of dependence in general practice. Part C1: Opioids. East Melbourne: The Royal Australian College of General Practitioners; 2017."},{"key":"10.1016\/j.ejpb.2022.10.002_b0095","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/JMDH.S38562","article-title":"Update on prescription extended-release opioids and appropriate patient selection","volume":"6","author":"Brennan","year":"2013","journal-title":"J Multidiscip Healthc."},{"issue":"12","key":"10.1016\/j.ejpb.2022.10.002_b0100","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1513\/AnnalsATS.201701-022OC","article-title":"The Critical Care Crisis of Opioid Overdoses in the United States","volume":"14","author":"Stevens","year":"2017","journal-title":"Ann Am Thorac Soc."},{"issue":"2","key":"10.1016\/j.ejpb.2022.10.002_b0105","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/dar.12595","article-title":"Counting the cost of over-the-counter codeine containing analgesic misuse: A retrospective review of hospital admissions over a 5 year period","volume":"37","author":"Mill","year":"2018","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.ejpb.2022.10.002_b0110","first-page":"7","article-title":"Australia bans non-prescription codeine to fight opioid crisis","volume":"2017","author":"Klein","year":"2017","journal-title":"New Sci."},{"key":"10.1016\/j.ejpb.2022.10.002_b0115","unstructured":"Australia's medicine labels are becoming clearer: TGA; 2020 [Available from: https:\/\/www.tga.gov.au\/australias-medicine-labels-are-becoming-clearer."},{"key":"10.1016\/j.ejpb.2022.10.002_b0120","article-title":"Opioid lawsuits: Sackler family agree final $6bn civil settlement with US states","volume":"376","author":"Dyer","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.ejpb.2022.10.002_b0125","first-page":"24","article-title":"Judge Rules Against Johnson & Johnson in Opioid Lawsuit","author":"Michael","year":"2019","journal-title":"Healio Rheumatol."},{"key":"10.1016\/j.ejpb.2022.10.002_b0130","article-title":"Global opioid lawsuits heading for $26B settlement","author":"Bronstad","year":"2021","journal-title":"BenefitsPRO."},{"key":"10.1016\/j.ejpb.2022.10.002_b0135","article-title":"Landmark $270 Million Opioid Lawsuit Settlement Opens Door for Dozens of Pending Cases. Healio","volume":"14","author":"Miller","year":"2019","journal-title":"Rheumatology"},{"issue":"24","key":"10.1016\/j.ejpb.2022.10.002_b0140","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1056\/NEJMp1710014","article-title":"Coupling Policymaking with Evaluation \u2014 The Case of the Opioid Crisis","volume":"377","author":"Barnett","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2022.10.002_b0145","unstructured":"B. Johnson. Addiction Medicine: Science and Practice. 2 ed: Elsevier Health Sciences; 2019."},{"key":"10.1016\/j.ejpb.2022.10.002_b0150","unstructured":"DEA and Partners Hold National Prescription Drug Take Back Day April 30 [press release]. Memphis, TN: U.S. Attorney\u2019s Office 2022."},{"key":"10.1016\/j.ejpb.2022.10.002_b0155","unstructured":"National Academies of Sciences Engineering and Medicine. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use. Bonnie RJ, Ford MA, Phillips JK, editors. Washington, DC: The National Academies Press; 2017."},{"issue":"7","key":"10.1016\/j.ejpb.2022.10.002_b0160","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1377\/hlthaff.2015.1496","article-title":"Implementation Of Prescription Drug Monitoring Programs Associated With Reductions In Opioid-Related Death Rates","volume":"35","author":"Patrick","year":"2016","journal-title":"Health Aff (Millwood)."},{"issue":"1","key":"10.1016\/j.ejpb.2022.10.002_b0165","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1257\/pol.20160094","article-title":"The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare","volume":"10","author":"Buchmueller","year":"2018","journal-title":"Am. Econom. J. Economic Policy."},{"issue":"1","key":"10.1016\/j.ejpb.2022.10.002_b0170","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMsa1514387","article-title":"State Legal Restrictions and Prescription-Opioid Use among Disabled Adults","volume":"375","author":"Meara","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ejpb.2022.10.002_b0175","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/jamainternmed.2015.0914","article-title":"Rates of Opioid Dispensing and Overdose After Introduction of Abuse-Deterrent Extended-Release Oxycodone and Withdrawal of Propoxyphene","volume":"175","author":"Larochelle","year":"2015","journal-title":"JAMA Internal Medicine."},{"issue":"3","key":"10.1016\/j.ejpb.2022.10.002_b0180","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1377\/hlthaff.2015.1025","article-title":"Medicare Letters To Curb Overprescribing Of Controlled Substances Had No Detectable Effect On Providers","volume":"35","author":"Sacarny","year":"2016","journal-title":"Health Aff (Millwood)."},{"issue":"5","key":"10.1016\/j.ejpb.2022.10.002_b0185","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.apergo.2009.12.005","article-title":"Designing packaging to support the safe use of medicines at home","volume":"41","author":"Ward","year":"2010","journal-title":"Appl. Ergon."},{"key":"10.1016\/j.ejpb.2022.10.002_b0190","doi-asserted-by":"crossref","unstructured":"B.Y. Tan, A.A. Shafie, M.A.A. Hassali, F. Saleem. Assessment of medication adherence and the costs associated with a calendar blister pack intervention among hypertensive patients in Malaysia: A randomized controlled trial. SAGE Open Med. 2017;5:2050312117709189.","DOI":"10.1177\/2050312117709189"},{"key":"10.1016\/j.ejpb.2022.10.002_b0195","unstructured":"R.D. Kay, inventor; Ronald D. Kay, assignee. Safety Closure Cevice For Medicine Container. USA patent US4452364. 1983."},{"key":"10.1016\/j.ejpb.2022.10.002_b0200","doi-asserted-by":"crossref","unstructured":"M.H. Schmidt, C.G. Nichols, E.W. Schmidt. Do child-resistant caps prevent school age children access to prescription medications? Ann Emerg Med. 2004;44(4, Supplement):S106.","DOI":"10.1016\/j.annemergmed.2004.07.344"},{"issue":"5","key":"10.1016\/j.ejpb.2022.10.002_b0205","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/ALN.0000000000002031","article-title":"Abuse-deterrent Opioid Formulations","volume":"128","author":"Litman","year":"2018","journal-title":"Anesthesiology"},{"issue":"11","key":"10.1016\/j.ejpb.2022.10.002_b0210","first-page":"46","article-title":"Abuse-Deterrent Opioids: What Practititoners Need to Know","volume":"33","author":"Rose","year":"2016","journal-title":"Federal Practitioner."},{"issue":"7","key":"10.1016\/j.ejpb.2022.10.002_b0215","first-page":"412","article-title":"A Review of Abuse-Deterrent Opioids For Chronic Nonmalignant Pain","volume":"37","author":"Moorman-Li","year":"2012","journal-title":"P&T."},{"issue":"1","key":"10.1016\/j.ejpb.2022.10.002_b0220","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijpharm.2016.06.012","article-title":"Recent advances in abuse-deterrent technologies for the delivery of opioids","volume":"510","author":"Maincent","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.10.002_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118629","article-title":"Multi-dose oral abuse deterrent formulation of loperamide using hot melt extrusion","volume":"569","author":"Nukala","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ejpb.2022.10.002_b0230","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1208\/s12249-020-01879-7","article-title":"Overdose and Alcohol Sensitive Immediate Release System (OASIS) for Deterring Accidental Overdose or Abuse of Drugs","volume":"22","author":"Patki","year":"2020","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.ejpb.2022.10.002_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121958","article-title":"Controlling drug release by introducing lipase inhibitor within a lipid formulation","volume":"623","author":"Murshed","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.10.002_b0240","doi-asserted-by":"crossref","unstructured":"T.P. Moyer. Medical Toxicology and Antidotes. In: Waldman SA, Terzic A, Egan LJ, Elghozi J-L, Jahangir A, Kane GC, et al., editors. Pharmacol Ther. Philadelphia: W.B. Saunders; 2009. p. 1213-1220.","DOI":"10.1016\/B978-1-4160-3291-5.50090-1"},{"issue":"3","key":"10.1016\/j.ejpb.2022.10.002_b0245","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/bcp.12793","article-title":"Activated charcoal for acute overdose: a reappraisal","volume":"81","author":"Juurlink","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.ejpb.2022.10.002_b0250","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1634\/theoncologist.2019-0340","article-title":"Dancing with Deterrents: Understanding the Role of Abuse-Deterrent Opioid Formulations and Naloxone in Managing Cancer Pain","volume":"24","author":"Mitchell","year":"2019","journal-title":"The Oncol."},{"key":"10.1016\/j.ejpb.2022.10.002_b0255","doi-asserted-by":"crossref","unstructured":"A. Colasanti, A. Lingford-Hughes, D. Nutt. Opioids Neuroimaging. In: Miller PM, editor. Biological Research on Addiction. 2. San Diego: Academic Press; 2013. p. 675-687.","DOI":"10.1016\/B978-0-12-398335-0.00066-2"},{"key":"10.1016\/j.ejpb.2022.10.002_b0260","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.addbeh.2018.03.014","article-title":"Opioid-overdose laws association with opioid use and overdose mortality","volume":"86","author":"McClellan","year":"2018","journal-title":"Addict. Behav."},{"key":"10.1016\/j.ejpb.2022.10.002_b0265","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1081\/CLT-200045006","article-title":"Position paper: gastric lavage","volume":"42","author":"Vale","year":"2004","journal-title":"J. Toxicol. Clin. Toxicol."},{"key":"10.1016\/j.ejpb.2022.10.002_b0270","series-title":"Small Animal Clinical Pharmacology","first-page":"469","article-title":"Gastrointestinal drugs","author":"German","year":"2008"},{"issue":"3","key":"10.1016\/j.ejpb.2022.10.002_b0275","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3109\/15563650.2013.770153","article-title":"Position paper update: ipecac syrup for gastrointestinal decontamination","volume":"51","author":"H\u00f6jer","year":"2013","journal-title":"Clin Toxicol."},{"key":"10.1016\/j.ejpb.2022.10.002_b0280","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.618411","article-title":"Advances in Oral Drug Delivery","volume":"12","author":"Alqahtani","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejpb.2022.10.002_b0285","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00002018-199410030-00005","article-title":"Novel Oral Drug Formulations","volume":"10","author":"Florence","year":"1994","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejpb.2022.10.002_b0290","doi-asserted-by":"crossref","unstructured":"Kostewicz ES, Vertzoni M, Benson HAE, Roberts MS, ProQuest. Oral Drug Delivery for Modified Release Formulations: Hoboken, NJ : John Wiley & Sons, Inc.; 2022.","DOI":"10.1002\/9781119772729"},{"key":"10.1016\/j.ejpb.2022.10.002_b0295","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fphar.2020.00524","article-title":"Advances in Oral Drug Delivery for Regional Targeting in the Gastrointestinal Tract - Influence of Physiological Pathophysiological and Pharmaceutical Factors","volume":"11","author":"Hua","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejpb.2022.10.002_b0300","doi-asserted-by":"crossref","first-page":"e14261","DOI":"10.1111\/nmo.14261","article-title":"Gastric half emptying time (T\u00bd) for 4-h gastric emptying scintigraphy simplifies reporting but reduces detection of gastroparesis","volume":"34","author":"Gardella","year":"2022","journal-title":"Neurogastroenterol. Motil."},{"issue":"4","key":"10.1016\/j.ejpb.2022.10.002_b0305","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/0016-5085(85)90569-4","article-title":"Measurement of gastric emptying time by real-time ultrasonography","volume":"89","author":"Bolondi","year":"1985","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejpb.2022.10.002_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105812","article-title":"Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review","volume":"162","author":"Vinarov","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.ejpb.2022.10.002_b0315","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3109\/00365521.2014.898326","article-title":"Surface area of the digestive tract \u2013 revisited","volume":"49","author":"Helander","year":"2014","journal-title":"Scand. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.ejpb.2022.10.002_b0320","first-page":"175","article-title":"The role of oral controlled release matrix tablets in drug delivery systems","volume":"2","author":"Nokhodchi","year":"2012","journal-title":"Bioimpacts."},{"issue":"1","key":"10.1016\/j.ejpb.2022.10.002_b0325","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ijpharm.2014.02.027","article-title":"In vitro duodenal lipolysis of lipid-based drug delivery systems studied by HPLC\u2013UV and HPLC\u2013MS","volume":"465","author":"Wulff-P\u00e9rez","year":"2014","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.ejpb.2022.10.002_b0330","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s11095-015-1661-y","article-title":"Solvent-free melting techniques for the preparation of lipid-based solid oral formulations","volume":"32","author":"Becker","year":"2015","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.ejpb.2022.10.002_b0335","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ijpharm.2011.03.002","article-title":"In vitro lipolysis models as a tool for the characterization of oral lipid and surfactant based drug delivery systems","volume":"417","author":"Larsen","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.10.002_b0340","unstructured":"N. Babul, inventor; Relmada Therapeutics Inc., assignee. Multimodal Abuse Resistant and Extended Release Opioid Formulations. USA patent US9125833. 2015."},{"key":"10.1016\/j.ejpb.2022.10.002_b0345","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2014.06.036","article-title":"Zein in controlled drug delivery and tissue engineering","volume":"189","author":"Paliwal","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2022.10.002_b0350","first-page":"9285854","article-title":"Protein Based Nanostructures for Drug Delivery","volume":"2018","author":"Verma","year":"2018","journal-title":"J. Pharm."},{"issue":"5","key":"10.1016\/j.ejpb.2022.10.002_b0355","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3390\/ma10050517","article-title":"Protein-Based Drug-Delivery Materials","volume":"10","author":"Jao","year":"2017","journal-title":"Materials."},{"key":"10.1016\/j.ejpb.2022.10.002_b0360","series-title":"Chemical Properties of Starch","article-title":"Starch Source and Its Impact on Pharmaceutical Applications","author":"Kunle","year":"2019"},{"issue":"2","key":"10.1016\/j.ejpb.2022.10.002_b0365","first-page":"59","article-title":"Starch as Pharmaceutical Excipient","volume":"41","author":"Hartesi","year":"2016","journal-title":"Int. J. Pharm. Sci. Rev. Res."},{"issue":"1","key":"10.1016\/j.ejpb.2022.10.002_b0370","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/02648725.2010.10648153","article-title":"Polysaccharide drug delivery systems based on pectin and chitosan","volume":"27","author":"Morris","year":"2010","journal-title":"Biotechnol. Genet. Eng. Rev."},{"issue":"9","key":"10.1016\/j.ejpb.2022.10.002_b0375","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1166\/jbn.2014.1950","article-title":"Carbohydrate Based Nanoparticles for Drug Delivery Across Biological Barriers","volume":"10","author":"Peptu","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.ejpb.2022.10.002_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2020.109607","article-title":"Carbohydrate polymer-based nanoparticle application in drug delivery for CNS-related disorders","volume":"128","author":"Ansari","year":"2020","journal-title":"Eur. Polym. J."},{"issue":"6","key":"10.1016\/j.ejpb.2022.10.002_b0385","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2174\/187152006778699130","article-title":"Recent Developments in Polymeric Nanoparticle Engineering and Their Applications in Experimental and Clinical Oncology","volume":"6","author":"Moein","year":"2006","journal-title":"Anticancer Agents Med Chem."},{"issue":"5","key":"10.1016\/j.ejpb.2022.10.002_b0390","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1203\/00006450-198405000-00002","article-title":"Fat Digestion by Lingual Lipase: Mechanism of Lipolysis in the Stomach and Upper Small Intestine","volume":"18","author":"Liao","year":"1984","journal-title":"Pediatr. Res."},{"issue":"4","key":"10.1016\/j.ejpb.2022.10.002_b0395","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/jps.24327","article-title":"Immobilised Lipase for In Vitro Lipolysis Experiments","volume":"104","author":"Phan","year":"2015","journal-title":"J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.ejpb.2022.10.002_b0400","doi-asserted-by":"crossref","first-page":"10904","DOI":"10.1021\/nn405123j","article-title":"Formation of Highly Organized Nanostructures during the Digestion of Milk","volume":"7","author":"Salentinig","year":"2013","journal-title":"ACS Nano"},{"issue":"6","key":"10.1016\/j.ejpb.2022.10.002_b0405","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.apsb.2013.10.001","article-title":"Oral lipid-based drug delivery systems - an overview","volume":"3","author":"Kalepu","year":"2013","journal-title":"Acta Pharm Sin B."},{"key":"10.1016\/j.ejpb.2022.10.002_b0410","first-page":"308","article-title":"A review on the food digestion in the digestive tract and the used in vitro models","volume":"4","author":"Sensoy","year":"2021","journal-title":"CRFS."},{"key":"10.1016\/j.ejpb.2022.10.002_b0415","first-page":"897","article-title":"Inhibitors of pancreatic lipase: State of the art and clinical perspectives","volume":"13","author":"Lunagariya","year":"2014","journal-title":"EXCLI J."},{"issue":"4","key":"10.1016\/j.ejpb.2022.10.002_b0420","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0016-5085(71)80065-3","article-title":"Pepsinogens, Pepsins, and Pepsin Inhibitors","volume":"60","author":"Samloff","year":"1971","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.ejpb.2022.10.002_b0425","first-page":"270","article-title":"Plant extracts are the potential inhibitors of \u03b1-amylase: a review","volume":"5","author":"Shah","year":"2018","journal-title":"MOJ Bioequiv."},{"issue":"12","key":"10.1016\/j.ejpb.2022.10.002_b0430","doi-asserted-by":"crossref","first-page":"6320","DOI":"10.1002\/fsn3.1987","article-title":"Inhibitors of \u03b1-amylase and \u03b1-glucosidase: Potential linkage for whole cereal foods on prevention of hyperglycemia","volume":"8","author":"Gong","year":"2020","journal-title":"Food Sci Nutr."},{"key":"10.1016\/j.ejpb.2022.10.002_b0435","doi-asserted-by":"crossref","unstructured":"M.L. Schubert, D. Kaunitz J. Gastric Secretion. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 9th ed. Philadelphia: W.B. Saunders; 2010. p. 817-832.","DOI":"10.1016\/B978-1-4160-6189-2.00049-4"},{"key":"10.1016\/j.ejpb.2022.10.002_b0440","unstructured":"J.M. Berg, J.L. Tymoczko, L. Stryer. Biochemistry. 5th ed. Moran S, Hadler GL, Zimmerman P, editors: W. H. Freeman and Company; 2002."},{"issue":"813","key":"10.1016\/j.ejpb.2022.10.002_b0445","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1098\/rstb.1970.0016","article-title":"On the mechanism of action of pepsin","volume":"257","author":"Knowles","year":"1970","journal-title":"Phil Trans Roy Soc Lond B."},{"issue":"7","key":"10.1016\/j.ejpb.2022.10.002_b0450","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/star.201000150","article-title":"Human \u03b1-amylase and starch digestion: An interesting marriage","volume":"63","author":"Butterworth","year":"2011","journal-title":"Starch\/St\u00e4rke."},{"issue":"1","key":"10.1016\/j.ejpb.2022.10.002_b0455","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0003-9861(67)90118-X","article-title":"Multiple attack hypothesis of \u03b1-amylase action: Action of porcine pancreatic, human salivary, and Aspergillus oryzae \u03b1-amylases","volume":"122","author":"Robyt","year":"1967","journal-title":"Arch. Biochem. Biophys."},{"issue":"4","key":"10.1016\/j.ejpb.2022.10.002_b0460","doi-asserted-by":"crossref","DOI":"10.3390\/pr10040780","article-title":"Evaluation of Porcine and Aspergillus oryzae \u03b1-Amylases as Possible Model for the Human Enzyme","volume":"10","author":"Marengo","year":"2022","journal-title":"Processes."},{"issue":"11","key":"10.1016\/j.ejpb.2022.10.002_b0465","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1093\/clinchem\/28.11.2201","article-title":"Mechanism of action of human pancreatic and salivary alpha-amylase on alpha-4-nitrophenyl maltoheptaoside substrate","volume":"28","author":"H\u00e4gele","year":"1982","journal-title":"Clin. Chem."},{"issue":"8","key":"10.1016\/j.ejpb.2022.10.002_b0470","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1055\/s-0030-1270924","article-title":"Natural Inhibitors of Pancreatic Lipase as New Players in Obesity Treatment","volume":"77","author":"de la Garza","year":"2011","journal-title":"Planta Med."},{"issue":"9555","key":"10.1016\/j.ejpb.2022.10.002_b0475","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0140-6736(07)60033-6","article-title":"Drug treatments for obesity: orlistat, sibutramine, and rimonabant","volume":"369","author":"Padwal","year":"2007","journal-title":"The Lancet."},{"issue":"1","key":"10.1016\/j.ejpb.2022.10.002_b0480","doi-asserted-by":"crossref","first-page":"G16","DOI":"10.1152\/ajpgi.2001.281.1.G16","article-title":"Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers","volume":"281","author":"Carri\u00e8re","year":"2001","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ejpb.2022.10.002_b0485","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jcis.2020.04.015","article-title":"Modulating the release of pharmaceuticals from lipid cubic phases using a lipase inhibitor","volume":"573","author":"Dully","year":"2020","journal-title":"J. Colloid Interface Sci."},{"issue":"1","key":"10.1016\/j.ejpb.2022.10.002_b0490","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.bbrc.2012.11.056","article-title":"Anti-elastolytic activity of a honeybee (Apis cerana) chymotrypsin inhibitor","volume":"430","author":"Kim","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.ejpb.2022.10.002_b0495","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.bbrc.2004.08.105","article-title":"Kinetic mechanism of protease inhibition by \u03b11-antitrypsin","volume":"323","author":"Kang","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"23","key":"10.1016\/j.ejpb.2022.10.002_b0500","doi-asserted-by":"crossref","first-page":"8951","DOI":"10.1021\/bi00449a001","article-title":"Implications of the three-dimensional structure of alpha1-antitrypsin for structure and function of serpins","volume":"28","author":"Huber","year":"1989","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.ejpb.2022.10.002_b0505","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/abbi.1997.0182","article-title":"Soybean Bowman-Birk Protease Inhibitor Is a Highly Effective Inhibitor of Human Mast Cell Chymase","volume":"344","author":"Ware","year":"1997","journal-title":"Arch. Biochem. Biophys."},{"issue":"4","key":"10.1016\/j.ejpb.2022.10.002_b0510","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s11130-016-0581-2","article-title":"Evaluation of Total Flavonoids, Myricetin, and Quercetin from Hovenia dulcis Thunb. As Inhibitors of \u03b1-Amylase and \u03b1-Glucosidase","volume":"71","author":"Meng","year":"2016","journal-title":"Plant Foods Hum. Nutr."},{"issue":"3","key":"10.1016\/j.ejpb.2022.10.002_b0515","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/cbic.200700470","article-title":"The Search for Novel Human Pancreatic \u03b1-Amylase Inhibitors: High-Throughput Screening of Terrestrial and Marine Natural Product Extracts","volume":"9","author":"Tarling","year":"2008","journal-title":"ChemBioChem"},{"issue":"3","key":"10.1016\/j.ejpb.2022.10.002_b0520","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1432-1033.1984.tb08221.x","article-title":"Tendamistat (HOE 467), a tight-binding \u03b1-amylase inhibitor from Streptomyces tendae 4158","volume":"141","author":"Vertesy","year":"1984","journal-title":"Eur. J. Biochem."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641122002211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641122002211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:51:23Z","timestamp":1760547083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641122002211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":104,"alternative-id":["S0939641122002211"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2022.10.002","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Existing and emerging mitigation strategies for the prevention of accidental overdose from oral pharmaceutical products","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2022.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}